Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Drug Profile

Anti-CD3/MUC1-armed cytokine induced killer cells - Benhealth Biopharmaceutical

Alternative Names: Activated CIK armed with anti-CD3-MUC1/CEA/EpCAM/GPC3 bispecific antibody; Anti-CD3/MUC1 antibody-armed PD-1 inhibitor-induced cytokine-induced killer cells; Anti-CD3/MUC1-armed PD-1 inhibitor-induced CIK cells; PD-1 activated CIK armed with anti-CD3/Anti-MUC1 bispecific antibody

Latest Information Update: 23 Feb 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Benhealth Biopharmaceutical
  • Class Bispecific antibodies; Cell therapies; Drug conjugates; Immunotherapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 23 Feb 2022 Phase II trial is still ongoing for Liver cancer (Late-stage disease) in China (NCT03146637)
  • 04 Jun 2021 Adverse events and efficacy data from a phase II trial in Liver cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)
  • 19 Oct 2020 Benhealth Biopharmaceutical withdraws a phase II trial in Gastric cancer (Late-stage disease) in China prior to enrolment (Parenteral) (NCT03554395)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top